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Access to high-impact mutations 
constrains the evolution of 
antibiotic resistance in soft agar
Nour Ghaddar1,2, Mona Hashemidahaj1 & Brandon L. Findlay  1
Despite widespread resistance to many important antibiotics, the factors that govern the emergence 
and prevalence of antibiotic-resistant bacteria are still unclear. When exposed to antibiotic gradients 
in soft agar plates measuring as little as 1.25 × 11 cm we found that Escherichia coli rapidly became 
resistant to representatives from every class of antibiotics active against Gram-negative bacteria. 
Evolution kinetics were independent of the frequency of spontaneous mutations that confer antibiotic 
resistance or antibiotic dose-response curves, and were only loosely correlated to maximal antibiotic 
concentrations. Instead, rapid evolution required unrealized mutations that could markedly decrease 
antibiotic susceptibility. When bacteria could not evolve through these “high-impact” mutations, 
populations frequently bottlenecked, reducing the number of cells from which mutants could arise and 
prolonging evolution times. This effect was independent of the antibiotic’s mechanism of action, and 
may affect the evolution of antibiotic resistance in clinical settings.
Antibiotic resistance is one of the greatest threats to modern medicine. Antibiotic-resistant organisms are thought 
to cause over 2,000,000 infections and 23,000 deaths in the United States each year1. Historically, preclinical 
assessment of new antibiotics has focused on measuring the rate with which resistance-conferring mutations 
occur in vitro2. Compounds with low or non-existent spontaneous resistance mutation rates are considered insen-
sitive to the evolution of resistance in vivo, to the extent that some may theoretically be “evolution-proof ”3,4. 
Unfortunately, clinical outcomes are less encouraging. The rate of spontaneous resistance development for clinical 
antibiotics span from 10−5 to 10−11 resistant mutations per cell per generation, and aren’t linked to the prevalence 
of resistance2. Rapid evolution of resistance during therapy also isn’t correlated to spontaneous resistance muta-
tion rates; the leucyl-tRNA synthetase inhibitor GSK2251052/AN3365 recently failed a phase II clinical trial after 
rapid evolution of drug resistance in vivo, despite a mutation rate of 1.4 × 10−7 5,6.
The recent development of laboratory evolution chambers has enabled directed evolution of bacteria without 
labour-intensive sub-culturing, allowing researchers to map the genotypic pathways to antibiotic resistance following 
growth in etched silicon wafers, moribodostats, and MEGA plates7–9. The latter has also revealed exciting evolution 
dynamics: bacteria growing in desk-sized MEGA plates encounter wedges of geometrically-increasing antibiotic con-
centrations up to 20,000x the initial MIC. In this environment, resistant mutants leave behind their susceptible breth-
ren, providing an excellent example of how competition for nutrients can drive the evolution of antibiotic resistance9.
Unfortunately, operating these devices requires a combination of specialized expertise and custom-built equip-
ment, limiting their throughput and general utility. To make the evolution of bacteria in vitro more accessible we 
have designed a compact system based on Soft Agar Gradient Evolution (SAGE). SAGE plates are built from stand-
ard petri dishes or similar labware, and can be run in high-throughput without ongoing operator involvement. We 
validated this system by generating mutants of Escherichia coli (E. coli) individually resistant to twelve antibiotics or 
antibiotic mixtures, covering every major antibiotic class active against Gram-negative bacteria. We then investi-
gated the kinetics of in vitro evolution, using the fine control over selective pressure provided by the SAGE system to 
determine the key factors governing the rate of antibiotic resistance. We found that successful strains often exhibited 
mutation rates distinct from their progenitors, and that mutation supply rates didn’t constrain evolution rates in even 
small bacterial populations. Instead, evolution rates appeared to be constrained by the limited availability of poten-
tial high-impact mutations, unrealized changes to the genome that could markedly increase antibiotic resistance.
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Results
Evolution chamber design. Hard agar gradient plates have been used since at least 1952 for antibiotic sus-
ceptibility testing10. They are created by sequentially pouring agar wedges of differing composition and allowing 
diffusion to equalize concentrations across the layers. By controlling the quantity of agar and the slope of the plate, 
it’s possible to create smooth gradients of arbitrary composition10,11. We found that these gradients are similarly 
stable at soft agar concentrations (0.2–0.75% agar w/v, Fig. 1), that allow bacteria to swim throughout the plate12. 
Bacteria inoculated into plates with antibiotic gradients grow until they encounter limiting concentrations of the 
antibiotic, at which point resistant mutants are selected for.
Movement through soft agar. To select for efficient chemotaxis, E. coli MG1655, BW25113 ΔmutL and 
BW25113 ΔmutS were passed three times through 0.25% agar plates, at which point they were able to traverse 
the plate within 20 hours of incubation at 37 °C. Adding a thin layer of mineral oil both reduced syneresis and 
decreased the experiment times to approximately 4 hr (Figs S1–3). Bacteria on oil-containing plates had lower 
densities, with growth restricted to the upper millimetre of the gel (Fig. S3). Increasing the strength of the agar 
decreased bacterial movement in accordance with previous work on the movement of E. coli in soft agar12, while 
decreasing the agar load led to gels that were too fragile to handle efficiently.
Using the antibiotic ciprofloxacin at 75 μg/L (~5x the initial bacterial minimum inhibitory concentration 
(MIC)), we then screened for the evolution of antibiotic resistance in SAGE plates. Circular petri dishes, square 
petri dishes, machined polycarbonate plates of varying widths, and rectangular 4-well nunclon-treated plates all 
gave similar results (Fig. S2), with resistant cells emerging after 24 hr of incubation at 37 °C. Due to the similarities 
in outcomes all further evolution studies were performed with 4-well nunclon-treated plates.
Time-lapse microscopy revealed that E. coli moved smoothly through the agar medium (Fig. S4), propagat-
ing in a wave of high density cells9,12. Entering agar free of other strains, mutants were able to quickly establish 
a buffer of discarded cells, blocking competition from faster growing but more antibiotic-susceptible cells. This 
Figure 1. Evolution of antibiotic resistance. (A) Immediately after pouring the agar layers form two distinct 
wedges, as shown with the dye malachite green as a visual indicator. (B) After 16 hr of incubation the two 
layers have intermixed to create a smooth gradient of the dye. (C) A top-down schematic, showing the site of 
inoculation and chemical gradient. (D) Changes in minimum inhibitory concentration following antibiotic 
exposure, minimum of three biological replicates. Speed-selected E. coli MG1655 cells were passed through 
SAGE plates containing the listed antibiotics at approximately 5x the initial MIC value. Those which evolved 
resistance were then passed through a separate plate containing 25x the initial MIC. Individual tests are shown 
in Table S1. Lineages derived from the first passage were named e.g. Poly B 1, Poly B 2, etc., and lineages built 
by passing evolved strains through the 25x plates were correspondingly named Poly B 1-1, Poly B 1–2, etc. 
*Bacteria were exposed to plates containing 10x and 50x the initial MIC of ciprofloxacin, and 20x and 100x the 
initial MIC of rifampicin, respectively. ‡Resistance was greater than 256x the initial MIC. Cells were uniformly 
resistant to 8192 mg/L of streptomycin, and poor solubility limited testing at higher drug concentrations.
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is similar to what was observed around the step gradients of MEGA plates9, and greatly reduced the impact of 
loss-of-fitness mutations, provided that these mutations also reduce antibiotic susceptibility.
Evolution of antibiotic resistance. When challenged with a variety of antibiotics at a minimum of 5x the 
MIC, antibiotic resistance emerged in the three E. coli strains under investigation: speed-selected variants of E. 
coli MG1655 and two strains with elevated mutation rates due to defects in their mismatch repair systems; E. coli 
BW25113 ΔmutS and ΔmutL13. The magnitude of resistance varied by antibiotic, from 4x to 512x the initial MIC 
(Fig. 1D, Tables S1–3. Lower levels of resistance could in some cases be further increased by exposing mutants to 
a second SAGE plate containing 25x the original MIC.
Resistance evolved against every antibiotic tested as well as co-trimoxazole, a 1:19 mixture of trimethoprim 
and sulfamethoxazole. This included representatives from every major class of antibiotics, as well as antibiotics 
that don’t readily evolve resistance in other in vitro systems. E.g. resistance to both doxycycline and chloram-
phenicol increased 32-fold following passage through their respective SAGE plates, versus a 10-fold increase 
in doxycycline resistance after twenty-five days of growth in a morbidostat (compared to a 870-fold increase in 
chloramphenicol resistance over the same time period)7. Similarly, the ease with which we developed resistance to 
drugs like ampicillin, doripenem, and polymyxin B is at odds with antibiotic resistance in the clinic, which often 
takes years to gain prevalence in bacterial pathogens14. Clinical resistance is also often linked to the transfer of 
plasmid-encoded inactivating proteins, which were absent in this study15. For example, resistance to beta-lactams 
in E. coli is largely due to the production of beta-lactamases, but we were able to readily obtain mutants resistant 
to ampicillin and doripenem despite the fact that E. coli MG1655 lacks an inducible beta-lactamase (though a 
copy of ampC is expressed at low levels)15–17.
Both MG1655 and the mutator strains developed resistance at similar levels (Fig. 1D, Tables S1–3). Counter 
to a theoretical model comparing evolution under uniform and increasing drug concentrations18, the bacterial 
strains rapidly evolved resistance to both ciprofloxacin and streptomycin, despite the different fitness effects of 
their resistance-conferring mutations. This may be because the strong founder effect of the system limits compe-
tition between naïve and resistant strains, as detailed above.
Genetic analysis. Amplification and sequencing of known proto-resistance genes identified several pre-
viously reported mutations in strains resistant to streptomycin, ciprofloxacin and trimethoprim (Tables S4 and 
S5). In particular, all four streptomycin-resistant lineages contained a K42R mutation in RpsL, which has been 
previously reported to confer near-immunity to streptomycin19,20. To evaluate broader genetic alterations we 
sequenced the genome of the progenitor strain of E. coli MG1655 and lineages resistant to ampicillin, gentamicin, 
or polymyxin B (Tables 1 and S6). The ancestral strain was found to have 78 mutations distinct from that of the 
previously published genome for E. coli MG165521. Some of these were likely acquired prior to this work, but 
there was an interesting V42A mutation in LrhA, a transcriptional repressor of bacterial motility. This mutation 
has not been previously reported, but mutants lacking lrhA show enhanced chemotaxis22. It’s possible that the 







AcrB F628L Aas D649G
AcrR G28R ElfG D140fsc





CpxA A97T HofM T133A
DinF W455R MalF Q115*




AcrB G861E Aas D649G
ArnC A192V AsmA R86C, E524fs
BamA Q441R, D447G HofM T133A
BasR G53E MalF Q115*
BasS L14P MalI T207A
Gmd F21L, T27C RfaH D106D
LptD G701R YfiM A106H
LpxC G106S
Table 1. Mutations identified through whole genome sequencinga. aFor a full list see Table S7. bStrains were 
collected following passage through the same 5x SAGE plate but different 25x plates. cMutation found in both 
lineages.
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Correcting for mutations in the ancestral strain, we found between 29 and 178 single nucleotide polymor-
phisms in the evolved strains (Table 1; a full list of mutations can be found in Table S6). In general, resistance 
appeared to be conferred not by any single genetic change but rather by the additive effects of a small series of 
mutations. For example, both ampicillin-resistant mutants contained a V545I mutation in penicillin-binding pro-
tein 3, FtsI. This mutation is linked to a roughly 3-fold increase in beta-lactam resistance in Salmonella spp.23, but 
the MIC of ampicillin rose 64-fold following passage through SAGE plates. The further increase in MIC appears 
to be related to missense mutations in the AcrAB efflux pump and its regulators, AcrR and MarR. Mutations in 
AcrR and MarR have been previously linked to a 4-fold increase in ampicillin resistance, by increasing expression 
of AcrAB and thereby reducing drug uptake24. Similarly, while the polymyxin B-resistant lineages contained a 
number of mutations in proteins involved in LPS biosynthesis or modification, they also contained mutations 
not previously linked to polymyxin B resistance, including in MalF, YfiM, and HofM. These proteins are found in 
the cell envelope, and may be involved in movement of polymyxin B across the membrane. Gentamicin and pol-
ymyxin B both traverse the outer membrane through self-promoted uptake25 and gentamicin-resistant lineages 
shared mutations in MalF and HofM (Table 1). Strains of E. coli deficient in malF and hofM were acquired from 
the Keio collection, but showed no appreciable difference in their MIC values to polymyxin B. The change in MIC 
conferred by these mutations may be lower than our limit of detection (one doubling of antibiotic concentration).
Mutation rate and population size. While no mutations in mismatch repair were observed during whole 
genome sequencing, we were concerned that passage through SAGE plates might select for mutators: strains with 
constitutively high mutation rates. We therefore determined the mutation rate of several strains before and after 
passage through SAGE plates, using the frequency of spontaneous resistance to rifampicin as a proxy measure-
ment (Table 2)26,27. Mutation rates for all three progenitor strains (MG1655, BW25113 ΔmutL and BW25113 
ΔmutS) were altered during the speed selection process, elevating the mutation rate of MG1655 while reducing 
the mutation rates of BW25113 ΔmutL and BW25113 ΔmutS. Subsequent passage through SAGE plates contain-
ing polymyxin B or ampicillin further altered the frequency of spontaneous resistance to rifampicin in MG1655, 
leading to lineages with rates both above (MG1655 Poly B 1 and 2) and below (MG1655 Poly B 1-1 and 1–2) that 
of the speed selected progenitor.
To gain a clearer picture of the mutation supply rate, we estimated the population size in SAGE plates. 
Representative samples from the growing front and stationary lawn of antibiotic-free SAGE plates were excised, 
and the cell counts in each sample were determined via qPCR using universal 16 S primers and a dilution stand-
ard of genomic E. coli DNA. qPCR is often used to measure populations of environmental bacteria28 and was 
favoured here as the bacterial cells of interest were embedded within an agar matrix. Relating our results back 
to the width of the excisions (~0.75 cm) and depth of the plate (0.45 cm), we found that a growing front contains 
approximately 1.31 × 107 cells/cm (s = 1.0 × 106), and that the density of cells behind this front is approximately 
5.98 × 107 cells/cm2 (s = 3.2 × 107). Only cells in the front are under selection, and so the maximal population 
under selection is 3.93 × 107 cells (s = 3.0 × 106). This value is likely to be an overestimate, both due to the likely 
presence of a small number of dead and dormant cells, and because during antibiotic selection the front often 
fragments into distinct lineages, creating a number of smaller sub-populations (see Fig. 3; below).
Factors governing the evolution of antibiotic resistance. Maximal antibiotic concentration and 
slope. The time required for bacteria to evolve antibiotic resistance was consistent across replicate experiments 
for each antibiotic investigated, but varied between drugs. To determine the factors that governed the evolution of 
resistance we began to vary the slope and concentration of antibiotic that bacteria were exposed to.
Increasing the maximal concentration of streptomycin in the plates from 5x MIC to 40x MIC and 320x MIC 
decreased growth across the plate during the first two days of incubation, but had no statistically significant effect 
on growth at 72 hours. (Fig. 2A). Other antibiotics showed a similar pattern, though with ciprofloxacin increasing 
the maximal drug concentration from 75x MIC to 125x MIC actually accelerated growth. This may be due to the 
mutagenic effect of subinhibitory ciprofloxacin concentrations, which could potentially increase the effective 
Lineage f (×108)b μ (×108)
MG1655 4.0 ± 2.1 1.1
MG1655 Post speed selectiona 64.6 ± 9.8 12.8
E. coli BW25113 ΔmutL 188 ± 4.3 31.1
E. coli BW25113 ΔmutL
Post speed selectiona 19.2 ± 12.8 4.3
E. coli BW25113 ΔmutS 650 ± 134.5 82.9
E. coli BW25113 ΔmutS
Post speed  selectiona 45.3 ± 4.0 7.8
Ampicillin 1-1 57.3 ± 27.7 18.3
Polymyxin B 1 312 ± 90 66.8
Polymyxin B 1-1 17.1 ± 6.2 6.4
Polymyxin B 1-2 15.6 ± 2.7 5.8
Polymyxin B 2 71.6 ± 13.4 19.9
Table 2. Frequency of spontaneous rifampicin resistance before and after antibiotic exposure. aAfter selection 
for efficient swimmers, prior to antibiotic exposure. bAverage of three technical replicates.
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mutant supply rate29. Of the antibiotics tested, only doxycycline showed a statistically significant difference in 
growth at 72 hr (10x MIC vs 50x MIC, s = 0.04, two-tailed, unequal variance Student’s t-test).
Increasing the slope of the antibiotic gradients from 8 mm to 12.5 mm also gave mixed results (Fig. 2B). No 
significant difference in movement rate was observed with plates containing trimethoprim, but differences of 
varying magnitude were observed in SAGE plates laced with ampicillin, doxycycline, and polymyxin B. The effect 
was pronounced with the latter two antibiotics at 25x the initial MIC, with much slower movement across the 
13 mm plates.
Antibiotic dose-response. In SAGE plates selective pressure is restricted to a narrow, high-density band of grow-
ing cells (Fig. S4; see above). Varying the maximal antibiotic concentration or slope may reduce the width of this 
band, constricting the population under selection and causing the prolonged experiment times we observed30. As 
Figure 2. Passage through SAGE plates as a function of (A) antibiotic concentration and (B) slope. Averages 
of three biological replicates are shown. Antibiotic concentrations are given as the maximal concentration in 
the plate, as a function of MIC. The slope in (A) was 8 mm. (B) The likelihood that the observed differences in 
movement were due to chance was calculated via a two-tailed unequal variance Student’s T test.*P value < 0.05, 
**P value < 0.01, ***P value < 0001, ****P value < 0.00001.
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changing the antibiotic concentration could also alter the mutations required for resistance we investigated the 
correlation between evolution time and band width through the antibiotic dose-response curve31. Compounds 
with steep dose-response curves will rapidly lower bacterial growth rates as the concentration of drug increases, 
reducing the width of the growing band. The antibiotic dose-response curve is also closely linked to the mutant 
selective window in other evolution systems, and is thought to contribute to the slow evolution rate of resistance 
against antimicrobial peptides like polymyxin B30,32.
However, we found no correlation between the dose-response curves of antibiotics and evolution rates 
(Table 3). Populations of fast-swimming E. coli MG1655 exposed to both doxycycline and polymyxin B required 
more time to traverse SAGE plates than populations exposed to ciprofloxacin or trimethoprim, though doxycy-
cline had the shallowest measured dose-response curve and polymyxin B the steepest.
The impact of resistance-conferring mutations determines evolution rates. At elevated antibi-
otic concentrations the dynamics of growth across SAGE plates changed. While bacteria still began by growing 
in a band of high-density cells, movement at growth-limiting concentrations of antibiotic was slow enough that 
individual mutation events were visible (Figs 3 and S4). Mutants first appeared as pinpricks of high density cells, 
growing over time into cones as cells radiated out from their point of origin. In trimethoprim plates these cones 
quickly coalesced into new bands of high-density cells, which moved across the plate until the concentration of 
antibiotic was again growth-limiting (Fig. S4).
Mutations were also observed in doxycycline plates, but the change in MIC provided by these mutations was 
much smaller. As a result, the majority of mutants didn’t form large cones, but instead stopped growing near the 
point of mutation, leaving behind small nodules of high-density cells (Fig. 3, arrows). Over several days the bacte-
ria in these nodules mutated further, increasing their resistance and allowing further movement across the plate. 
Increasing the plate’s slope significantly compressed the nodules, reducing the population that could give rise to 
highly-resistant mutants. This in turn increased the amount of time required for doxycycline resistance to evolve.
Thus, the rate of evolution in SAGE plates is set by the change in antibiotic susceptibility conferred by unre-
alized mutations. Latent “high-impact” mutations allow strains to re-establish large populations following 
Antibiotic N value
Median Time to Completiona
15 × MIC 25 × MIC
Ciprofloxacin 3.2 2 2
Doxycycline 1.3 3 5
Polymyxin B 32.2 3 6
Trimethoprim 3.3 2 2
Table 3. Antibiotic dose-response and evolution rates. aMedian of three biological replicates. All values in days. 
N values for E. coli MG1655 were calculated after speed selection. Large N values correspond to steep dose 
response curves.
Figure 3. Visual observation of resistance to doxycycline. SAGE plates were incubated at 37 °C for seven days. 
Shown here is one representative lane, containing up to 25x the initial MIC of doxycycline at a slope of 12.5 mm. 
Nodules of resistant cells observed on day 2 are marked by arrows. With high concentrations of doxycycline, 
many of these mutations conferred only a small increase in MIC, leading to small populations of moderately 
resistant bacteria. Large bacterial populations did not reform until day 5.
www.nature.com/scientificreports/
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antibiotic challenge, ensuring that if the concentration of antibiotic once again becomes growth limiting there is 
a large population from which further mutants can arise. When resistance is conferred by low-impact mutations, 
the bacteria become trapped in population bottlenecks, reducing the likelihood of further mutations.
With this new framework, we can explain the rapid evolution of bacteria exposed to high levels of ciproflox-
acin, trimethoprim, and streptomycin. Resistance to each of these antibiotics is known to occur from a small 
number of high-impact mutations19,33,34, several of which were observed in strains following passage through 
SAGE plates (Table S5). In principle, any antibiotic whose activity can be sharply curtailed by a small number of 
high-impact mutations will be quickly rendered ineffective by SAGE, regardless of the spontaneous resistance 
mutation rate or maximal antibiotic concentration.
Population mutation rates appear to vary within SAGE plates. The population bottlenecks that 
antibiotics create within SAGE plates may be partially alleviated by transiently increasing the mutation supply 
rate by rapid cell turnover35. Antibiotic stress is also known to trigger transiently elevated mutation rates through 
the SOS response, the stringent response, and the production of reactive oxygen species36–38. However, our work 
suggests that in SAGE plates these bacteria may also improve their mutation supply rate through the transient 
evolution of strains with high background mutation rates.
High mutation rates are known to help populations more easily develop antibiotic resistance37, and muta-
tor strains are more prevalent in populations of bacterial pathogens39,40. However, we found that mutators were 
uncommon following exposure of speed selected E. coli MG1655 to gradients of polymyxin B, and that simple 
passage of E. coli BW25114 ΔmutS through antibiotic-free agar was sufficient to drop the observed mutation rate 
14-fold, bringing it close to values recorded for the other strains investigated (Table 2, see above). High mutation 
rates can reduce fitness in the absence of stress40,41 and we hypothesize that this is leading to counter-selection 
later in the plate, when the bulk of the population is antibiotic resistant.
Similar behaviour has been recently observed in E. coli populations exposed to ethanol stress, where popu-
lation mutation rates frequently rose and fell in response to increasing ethanol concentrations42. If this process 
is occurring in the SAGE system it could explain why we observed relatively small populations of both wildtype 
progenitor strains and progenitors with mutator phenotypes rapidly developing resistance to antibiotics with low 
spontaneous resistance mutation rates.
Other environments. Extending these results to bacterial evolution in other systems, access to high-impact 
mutations may broadly constrain the in vitro evolution of antibiotic resistance. Resistant mutants are often less 
fit, and in liquid environments like that of morbidostats don’t form a significant fraction of the population until 
the antibiotic significantly inhibits susceptible strains43. When bacteria evolve resistance through a series of 
low-impact mutations these in vitro systems may be unable to distinguish between the susceptibility of naïve and 
resistant strains. This may be the case with doxycycline resistance, which generally doesn’t exceed 10x the initial 
MIC following either serial passage through liquid media or growth in a morbidostat7,44. The low-level mutants 
we observed in SAGE plates may occur in these systems, but the concentration of doxycycline needed to inhibit 
the growth of susceptible strains will likely inhibit the mutants as well, preventing them from forming the major-
ity of the population or evolving elevated levels of resistance.
Discussion
Using antibiotic gradients in soft agar we evolved mutants of E. coli resistant to representatives of every major 
class of antibiotic active against Gram-negative bacteria. Our findings show that in soft agar gradients evolution 
kinetics are constrained by the potential for high-impact mutations. When bacteria develop resistance through 
high-impact mutations, as with streptomycin resistance, bacteria quickly recover from population bottlenecks 
following selection, easing passage through future selective barriers. In contrast, factors that have been previously 
linked to the rate of resistance development, such as the maximal antibiotic concentration, spontaneous resistance 
mutation frequency, and antibiotic dose-response/mutant selection window had little influence on evolutionary 
success. Their limited impact in the SAGE plates appears to be in part due to the transient evolution of strains 
with elevated mutation rates, which increases the mutation supply rate and allows for the generation of resistant 
mutants from even small bacterial populations. In the absence of antibiotic stress these hypermutators appear to 
be rapidly replaced by strains with lower mutation rates.
Natural environments are unlikely to contain semi-solid agar gels, but will likely contain antibiotic gradients, 
potentially allowing for evolutionary dynamics similar to what we have observed. In particular, the human body 
readily creates drug gradients during both antibiotic therapy and chemotherapy, due to limited penetration into 
various tissues45–47. If these gradients accelerate the evolution of resistance in vivo, this likely explains why our 
current methods of evaluating potential new antibiotics are poorly correlated to clinical outcomes2. To reduce the 
emergence of resistance, antibiotic candidates should instead be evaluated by their potential to be nullified by a 
small number high-impact mutation. Those which lack such convenient resistance pathways will be less suscep-
tible to the evolution of resistance.
Experimental Procedures
Soft agar gradient evolution plates. Sterile 4-well nunclon treated culture dishes were purchased from 
Thermo Scientific (cat. 167063), and used for the majority of evolution experiments. The hydrophilic surface 
treatment was not critical for SAGE experiments, but led to more resilient gels due to increased interactions 
between gel and plate.
Strains. E. coli MG1655 was a generous gift from Éric Déziel, INRS, Canada. E. coli BW25113 ∆mutS and 
∆mutL were purchased from the Coli Genetic Stock Center (CGSC) and are part of the Keio Collection13.
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Soft agar gradient evolution experiments. Molten 0.25% cation-adjusted Mueller-Hinton agar (MHA) 
was poured into 4-well plates that were raised on one side 3 mm, 8 mm, or 12.5 mm. Convenient lifters were made 
from P200 pipette tips, P1000 pipette tips, or a 1/2” role of labeling tape, respectively. Agar was added to half the 
height of the well on the lower side (0.45 cm), then left to gel at room temperature for 20 minutes. The supports 
were then removed and a second agar solution was added to an even depth. Plates were incubated overnight at 
room temperature to allow diffusion between the two layers.
To initiate experiments up to 50 µL of an overnight bacterial culture was inoculated in a line on the side of the 
well where the concentration of antibiotic was lowest. The wells were then covered with up to 5 mL of mineral oil 
to prevent desiccation and incubated at 37 °C.
After cells had grown throughout the plate mutants were harvested by sampling relevant regions of the plate 
via pipette. The soft agar extracted was then added to 5 mL of cation-adjusted Mueller-Hinton Broth (MHB) and 
incubated overnight at 37 °C. Cells were stored at −80 °C in glycerol or used for further experiments.
Minimum inhibitory concentration measurements. Populations extracted from SAGE plates were 
assessed following standard microdilution procedures48. In brief, 50 µL of cation-adjusted MHB containing the 
antibiotic of interest was mixed 1:1 with fresh media containing approximately 1 × 106 bacterial cells (verified 
against a freshly prepared McFarland 0.5 standard) to give a final cell density of 5 × 105 CFU. Plates were then 
incubated at 37 °C for 16–20 hours. Wells lacking bacteria were used as negative controls, and wells with bacteria 
and without antibiotic were used as positive controls. The MIC was defined as the minimum concentration of 
antibiotic that results in no visible growth to the naked eye.
Dose response curves and growth rate measurements. To measure the growth rate of E.coli in the pres-
ence of different concentrations of each antibiotic, bacteria were added to 96-well plates as described above. The 
plates were then sealed with parafilm and incubated at 30 °C in a Tecan Sunrise plate reader running Magellan V 7.1. 
Absorbance was measured at 595 nm every 30 seconds, with 15 seconds of shaking and two seconds of settle time prior 
to each measurement. Measurements were collected for 23 hours. The data was then exported to Excel. Measurements 
were zeroed and converted to their natural log. The steepest region of the growth curve was then determined, and a 
minimum of forty measurements were then fit to a linear curve. These dose response curves were then plotted against 













where, g(c) is growth rate as a function of antibiotic concentration, c, g0 is the growth rate in the absence of anti-
biotic, and IC50 is the concentration of antibiotic where the growth rate was half g0, n is the hill co-efficient, and 
corresponds to how quickly growth decreases as the antibiotic concentration increases.
Mutation rates. To infer the mutation rate of evolved E. coli lineages we measured the frequency of sponta-
neous resistance to rifampicin26. In brief, each strain was grown in MHB media overnight. Cells were then diluted 
in fresh MHB and plated in triplicate onto either LB-agar or LB-agar with 100 µg/mL rifampicin. The plates were 
incubated for 16–20 hours at 37 °C, and the number of colonies on each was counted. The median frequency, f, of 
each strain was then calculated and used to determine the median mutation rate, μ, based on the formula:
µμ = ln Nf/ ( )
where N is the total population, determined by counting cells grown on rifampicin-free agar26,50.
Whole genome sequencing. Strains of interest were grown overnight in MHB, then genomic DNA was 
extracted using the EZ-10 Bacterial Genomic DNA miniprep kit according to manufacturer’s specifications. 
Samples were sequenced by Genome Quebec on an Illumina HiSeq. 4000 PE100. Sequence data was then assem-
bled with the A5-miseq pipeline software. Snippy was used to compare the genome assemblies to the reference 
genome of E. coli MG1655, U00096.3 (https://github.com/tseemann/snippy).
Population size calculations. SAGE plates free of antibiotic were inoculated with 50 μL of E. coli MG1655, then 
incubated at 37 °C for four hours. Agar blocks containing representative bands and bacterial lawns were then excised 
with a sterile spatula and heated at 98 °C for five minutes. Cells were mixed 1:10 with distilled, deionized water, heated 
at 98 °C for three more minutes, and then used as template for qPCR. In brief, 1 μL of template was mixed with 14.6 μL 
ddH2O, 4 μL 5X EvaGreen qPCR mix, 0.4 μL forward primer (0.1 μM, 16 S F27) and 0.4 μL reverse primer (0.1 μM, 16 S 
R1492)51. The thermal profile used was 15 min of polymerase activation at 95 °C followed by the PCR cycling stage with 
40 cycles (95 °C for 45 sec, 55 °C for 30 sec, 72 °C for 1 min) and ending with a melting curve (95 °C for 15 sec, 55 °C for 
15 sec, 95 °C for 15 sec). Results from a dilution series of genomic DNA were used to determine the cell copy numbers.
For cells extracted from the growing front, the reported number of cells was multiplied by 10 to account 
for the initial dilution, then standardized to the total volume of the excised gel band. This population was then 
divided by the width of the excised band (~0.75 cm) to give a cell count per cm of the growing front. Values 
corresponding to cells extracted from the lawn were multiplied by 10, divided 0.05 mL and multiplied by sqrt 
(1 cm3/0.45 cm) = 1.49 cm2 to adjust for the depth of the agar (0.45 cm). The total population of the growing front 
was estimated by multiplying the width of the lane (2.9 cm), the width of the growing front in the absence of 
antibiotic (0.3 cm) and the depth of the agar which contained cells (0.1 cm). Results are presented as the average 
of three independent replicates.
www.nature.com/scientificreports/
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Data Availability
Full MIC testing results and whole-genome sequencing data are included in the supplementary information files.
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